文献类型：期刊文献

中文题名：跌打七厘片治疗急性软组织损伤临床应用专家共识

英文题名：Expert consensus on clinical application of Dieda Qili Tablets in treatment of acute soft tissue injury

作者：秦晓宽[1];魏戌[1,2];赵继荣[3];王培民[4];于杰[1,2];李宇卫[5];王尚全[1,2];李玲慧[1,2];朱立国[1,2]

第一作者：秦晓宽

机构：[1]中国中医科学院望京医院,北京100102;[2]中医正骨技术北京市重点实验室,北京100102;[3]甘肃中医药大学,甘肃兰州700030;[4]南京中医药大学附属医院,江苏南京210004;[5]南京中医药大学附属苏州市中医医院,江苏苏州215007

第一机构：中国中医科学院望京医院,北京100102

年份：2024

卷号：49

期号：18

起止页码：5076

中文期刊名：中国中药杂志

外文期刊名：China Journal of Chinese Materia Medica

收录：CSTPCD;;Scopus;北大核心:【北大核心2023】；CSCD:【CSCD2023_2024】；PubMed;

基金：中国中医药循证能力提升项目(ZZ13-024-7)。

语种：中文

中文关键词：急性软组织损伤;跌打七厘片;专家共识;中成药;GRADE系统

外文关键词：acute soft tissue injury;Dieda Qili Tablets;expert consensus;Chinese patent medicine;GRADE system

摘要：跌打七厘片是国家中药保护品种、医保乙类品种,临床上广泛用于治疗急性软组织损伤,受多部丛书推荐,但目前尚无基于循证证据制订的指南或共识指导跌打七厘片的临床应用。在中华中医药学会的支持下,由中国中医科学院望京医院牵头,联合国内21家单位,遵循“循证为主,共识为辅,经验为鉴”的指导思想编制该共识。对全国范围内多名临床专家和一线医生开展访谈和调研,通过名义组法确定需解决的临床问题。根据临床问题系统检索临床研究证据,采用GRADE系统进行证据质量评价,最后通过名义组法对推荐意见/共识建议达成共识。该共识明确了跌打七厘片治疗急性软组织损伤的临床应用范围、使用方法、安全性、联合用药及研究进展等,适用于全国三级医院、二级医院、基层医疗卫生机构的临床医师(包括中医、西医、中西医结合专业),可为其合理使用跌打七厘片治疗急性软组织损伤提供指导和参考。目前,该共识已通过中华中医药学会标准化办公室审查并发布,标准号GS/CACM 347-2024。
Dieda Qili Tablets are protected traditional Chinese medicine(TCM)variety and type B medicine included in medical insurance in China,which is widely used in the treatment of acute soft tissue injury in clinical practice and has been recommended by many books.However,there is no evidence-based guideline or consensus to guide the clinical application of Dieda Qili Tablets.With the support of China Association of Chinese Medicine,Wangjing Hospital of China Academy of Chinese Medical Sciences led the 21 Chinese units to follow the guiding ideology of"evidence as the key,consensus as the supplement,and experience as the reference"to compile this consensus.Interviews and surveys were conducted among a number of clinical experts and front-line doctors across the country,and the clinical problems to be solved were determined through the nominal group method.According to the clinical questions,the evidence of clinical studies was systematically retrieved.The GRADE system was used to evaluate the quality of the evidence,and finally,the recommendation/consensus suggestion was reached through the nominal group method.This consensus clarified the clinical application scope,usage methods,safety,combination medication,and research progress of Dieda Qili Tablets in the treatment of acute soft tissue injury,and it is applicable to clinicians in tertiary hospitals,secondary hospitals,and primary medical and health institutions(TCM,western medicine,and integrated traditional Chinese and western medicine).It provides guidance and refe-rence for the rational use of Dieda Qili Tablets in the treatment of acute soft tissue injury.At present,this consensus has been reviewed and published by the Standardization Office of China Association of Chinese Medicine,with a standard number of GS/CACM 347-2024.